Loading company…
Somagenetix develops gene therapies for disorders involving phagocytes.
Based in Zurich, Switzerland, Somagenetix develops gene therapies for phagocyte-related disorders, including immunodeficiency, neurodegeneration, and cancer. Its approach uses lentivirus-transduced stem cells to pursue one-time treatments. In October 2024, the company raised CHF 10 million in Series A funding led by Vi Partners, with participation from Schroders Capital, Zürcher Kantonalbank, and Verve Ventures. The funding will advance SGX-001 toward clinical trials for p47 Chronic Granulomatous Disease.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in